Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Research

Fabry disease and incidence of cancer

Authors: Sarah Bird, Efthymios Hadjimichael, Atul Mehta, Uma Ramaswami, Derralynn Hughes

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Background

Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of α-galactosidase A and the resulting accumulation of the glycosphingolipid globotriaosylceramide (Gb3) and its derivatives, including globotriaosylsphingosine (Lyso-Gb3). Increased cellular and plasma levels of Gb3 and Lyso-Gb3 affect multiple organs, with specific clinical consequences for the kidneys, heart and brain.
There is growing evidence that alterations in glycosphingolipids may have an oncogenic role and this prompted a review of cases of cancer and benign lesions in a large single centre cohort of Fabry patients. We also explored whether there is a difference in the risk of cancer in Fabry patients compared to the general population.

Results

Our results suggest that Fabry patients may have a marginally reduced rate of all cancer (incidence rate ratio 0.61, 95% confidence interval 0.37 to 0.99) but possibly increased rates of melanoma, urological malignancies and meningiomas.

Conclusion

Greater knowledge and awareness of cancer in patients with Fabry disease may help identify at-risk individuals and elucidate cancer mechanisms in this rare inherited disease, which may potentially be relevant to the wider cancer population.
Literature
1.
2.
Deegan PB, Baehner AF, Romero MÁ, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43(4):347–52.CrossRefPubMed
3.
Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44–54.CrossRefPubMed
4.
Elstein D, Schachamorov E, Beeri R, Altarescu G. X-inactivation in Fabry disease. Gene. 2012;505(2):266–8.CrossRefPubMed
5.
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Ntl Acad Sci. 2008;105(8):2812–7.CrossRef
6.
Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, Elliott PM, Linthorst GE, Wijburg FA, Biegstraaten M, Hollak CE. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2016;15
7.
Lee CJ, Fan X, Guo X, Medin JA. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol. 2011;57(1):115–22.CrossRefPubMed
8.
9.
Hakomori SI. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res. 1996;56(23):5309–18.PubMed
10.
Hakomori S. Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol. 2003;10(1):16–24.CrossRefPubMed
11.
Johansson D, Kosovac E, Moharer J, Ljuslinder I, Brännström T, Johansson A, Behnam-Motlagh P, Johansson D. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer. 2009;9(1):67.CrossRefPubMedPubMedCentral
12.
Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon M, Robine S, Joahnnes L, Janssen K. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther. 2008;7(8):2498–508.CrossRefPubMed
13.
Distler U, Souady J, Hülsewig M, Drmić-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, Schmidt MA, Peter-Katalinić J, Müthing J. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS One. 2009;4(8):e6813.CrossRefPubMedPubMedCentral
14.
Sawada R, Hotta H, Chung YS, Sowa M, Tai T, Yano I. Globotriaosyl ceramide and globoside as major glycolipid components of fibroblasts in scirrhous gastric carcinoma tissues. Cancer Sci. 1998;89(2):167–76.
15.
Arab S, Russel E, Chapman WB, Rosen B, Lingwood CA. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res Featuring Preclin Clin Cancer Ther. 1997;9(10):553–63.
16.
Kang J, Rajpert-De Meyts E, Skakkebæk N, Wiels J. Expression of the glycolipid globotriaosylceramide (Gb3) in testicular carcinoma in situ. Virchows Arch. 1995 May;426(4):369–74.CrossRefPubMed
17.
Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53(21):5314–9.PubMed
18.
Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, Kane A, Donowitz M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Pro National Acad Sci U S A. 2005;102(52):19087–92.CrossRef
19.
Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31(1):67–76.CrossRefPubMed
20.
Gangoiti P, Granado MH, Alonso A, Goñi FM, Gómez-Muñoz A. Implication of ceramide, ceramide 1-phosphate and sphingosine 1-phosphate in tumorigenesis. Transl Oncogenomics. 2008;3:81.PubMedPubMedCentral
21.
Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev™ Oncogenesis. 2013;18(3):235–46.CrossRef
22.
De Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Häussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36(1):53–8.CrossRefPubMed
23.
Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84(4):208–14.CrossRefPubMedPubMedCentral
24.
Choy FY, Campbell TN. Gaucher disease and cancer: concept and controversy. International J Cell Biol. 2011;7:2011.
25.
Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher registry. Blood. 2005;105(12):4569–72.CrossRefPubMed
26.
Cybulla M, Kleber M, Walter KN, Kroeber SM, Neumann HP, Engelhardt M. Is Fabry disease associated with leukaemia? British J Haematol. 2006;135(2):264–5.CrossRef
27.
Pagni F, Pieruzzi F, Zannella S, Di Giacomo A, Bovo G, Ferrario F, Torti G, Rivera R, Assi E, Viglione F, Nebuloni M. Possible pathogenetic relationship between Fabry disease and renal cell carcinoma. Am J Nephrol. 2012;36(6):537–41.CrossRefPubMed
28.
Tisi MC, Zampetti A, Feliciani C, Fianchi L, Valentini CG, Hohaus S, Larocca LM, Leone G, Voso MT. Small lymphocytic lymphoma in a patient with Fabry disease. Leuk Lymphoma. 2013;54(1):184–5.CrossRefPubMed
29.
Blanco J, Herrero J, Arias LF, Garcia-Miralles N, Gamez C, Barrientos A. Renal variant of Anderson-Fabry disease and bilateral renal cell carcinoma. Pathology-Research and Practice. 2005;200(11):857–60.CrossRef
30.
Cassiman D, Claes K, Lerut E, Oyen R, Joniau S, Van Damme B, Jaeken J. Bilateral renal cell carcinoma development in long-term Fabry disease. J Inherit Metab Dis. 2007;30(5):830.CrossRefPubMed
31.
Rothman KJ, Greenland S, Lash TL. Modern epidemiology third edition: Lippincott Williams & Wilkins, Philadelphia USA; 2008.
32.
33.
De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide. Mol Genet Metab. 2011;104(3):319–24.CrossRefPubMed
34.
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.CrossRefPubMed
35.
Papaxanthos-Roche A, Deminière C, Bauduer F, Hocké C, Mayer G, Lacombe D. Azoospermia as a new feature of Fabry disease. Fertil Steril. 2007;88(1):212–e15.CrossRefPubMed
36.
Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB, FOS investigators. Fabry disease and the skin: data from FOS, the Fabry outcome survey. British J Dermatol. 2007;157(2):331–7.CrossRef
37.
Thurberg BL, Germain DP, Perretta F, Benistan K, Politei JM. Meningioma in Fabry disease: three case reports and a review of the literature on malignancies in patients with metabolic lipid disorders. Mol Genet Metab. 2016;117(2):S112.CrossRef
Metadata
Title
Fabry disease and incidence of cancer
Authors
Sarah Bird
Efthymios Hadjimichael
Atul Mehta
Uma Ramaswami
Derralynn Hughes
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0701-6

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue

Letter to the Editor

Probable DRESS syndrome induced by IL-1 inhibitors

Research

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

Research

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome

Letter to the Editor

PIGO deficiency: palmoplantar keratoderma and novel mutations

Research

STUB1/CHIP mutations cause Gordon Holmes syndrome as part of a widespread multisystemic neurodegeneration: evidence from four novel mutations

Research

Re-evaluation of hypoplastic left heart syndrome from a developmental and morphological perspective